1300 / 1840
• There were no significant differences in local control, distant control, or
overall survival by reirradiation interval, treatment platform (cyberknife
Vargo et al, IJROBP 2015
/Triology/ Truebeam), or second primary versus local recurrence.
• Recurrent GTV (<25 cm3) was associated with significantly improved
locoregional PFS (1 year, 53%, and 22%, p 0.029%) and overall survival (1
year, 70%, and 22%,p <0.01).
• The combination of 40 to 44 Gy over 5 fractions plus 3 doses of Cetuximab
translated into a 67% relative increase in median OS (10 vs. 6 months ) with
acceptable toxicity compared to previous phase I study.
• Short overall treatment time and low rates of acute toxicity which allow
patients with a generally poor prognosis to complete a potentially aggressive
salvage therapy without compromising QoL